Mood and Cognitive Disorders in Cancer Patients Receiving Cytokine Therapy

  • Christina A. Meyers
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 461)


The use of cytokines, especially interferon-α (IFN-α) and interleukin-2 (IL-2) to treat malignancies and chronic viral infections is broadening, and increasing attention is being paid to the effects of these agents on the central nervous system (CNS). It is now known that cytokine therapy can be associated with the development of cognitive and psychiatric adverse effects that range from subtle impairments of attention and memory undetectable on routine medical evaluation to delirium and psychosis. Because IFN-α is a highly effective therapy in certain diseases, it is important that patients continue on treatment at effective doses. Understanding the nature, incidence, severity, and mechanisms of CNS effects is essential to develop interventions to decrease morbidity while maintaining patients on treatment.


Chronic Myelogenous Leukemia Verbal Memory Cognitive Disorder Minnesota Multiphasic Personality Inventory Central Nervous System Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amato, R., Meyers, C., Ellerhorst, J., Finn, L., Kilbourn, R., Sella, A., & Logothetis, C. (1995). A phase I trial of intermittent high-dose α-interferon and dexamethasone in metastatic renal cell carcinoma. Annals of Oncology, 6, 911–914.PubMedGoogle Scholar
  2. Cummings, J. L. (1990). Subcortical Dementia. New York: Oxford University Press.Google Scholar
  3. Dalakas, M. C., Mock, V., & Hawkins, M. J. (1998). Fatigue: definitions, mechanisms, and paradigms for study. Seminars in Oncology, 25Supplement 1, 48–53.PubMedGoogle Scholar
  4. Goldman, L. S. (1994). Successful treatment of interferon alfa-induced mood disorder with nortriptyline (Letter to the editor). Psychosomatics, 35, 412–413.PubMedGoogle Scholar
  5. Ho, B. T., Lu, J. G., Huo, Y. Y., Fan, S. H., Meyers, C. A., Tansey, L. W., Payne, R., & Levin, V. A. The opioid mechanism of interferon-α action. Anti-Cancer Drugs, 5, 90–94.Google Scholar
  6. Jones, T. H. J., Wadler, S., & Hupart, K. H. (1998). Endocrine-mediate mechanisms of fatigue during treatment with interferon-α. Seminars in Oncology, 25Supplement 1, 54–63.PubMedGoogle Scholar
  7. Levenson, J. L. & Fallon, H. J. (1993). Fluoxetine treatment of depression caused by interferon-alpha. American Journal of Gastroenterology, 88, 760–761.PubMedGoogle Scholar
  8. Licinio, I, Kling, M. A., & Hauser, P. (1998). Cytokines and brain function: relevance to interferon-α-induced mood and cognitive changes. Seminars in Oncology, 25Supplement1, 30–38.PubMedGoogle Scholar
  9. Mapou, R. L., Law, W. A., Wagner, K., Malone, J. L., & Skillman, D. R. (1996). Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. Journal of Neuropsychiatry and Clinical Neurosciences, 8, 74–81.PubMedGoogle Scholar
  10. Meyers, C. A. & Abbruzzese, J. L. (1992). Cognitive functioning in cancer patients: effect of previous treatment. Neurology, 42, 434–436.PubMedGoogle Scholar
  11. Meyers, C. A. & Valentine, A. D. (1995). Neurologic and psychiatric adverse effects of immunological therapy. CNS Drugs, 3, 56–68.CrossRefGoogle Scholar
  12. Meyers, C. A., Valentine, A. D., Wong, F. C. L., & Leeds, N. E. (1994). Reversible neurotoxicity of interleukin-2 and tumor necrosis factor: correlation of SPECT with neuropsychological testing. Journal of Neuropsychiatry and Clinical Neurosciences, 6, 285–288.PubMedGoogle Scholar
  13. Meyers, C. A. & Yung, W. K. A. (1993). Delayed neurotoxicity of intraventricular interleukin-2: a case report. Journal of Neuro-Oncology, 15, 265–267.PubMedCrossRefGoogle Scholar
  14. Meyers, C. A., Obbens, E. A. M. T., Scheibel, R. S., & Moser, R. P. (1991). Neurotoxicity of intraventricularly administered alpha interferon for leptomeningeal disease. Cancer, 68, 88–91.PubMedCrossRefGoogle Scholar
  15. Meyers, C. A., Scheibel, R. S., & Forman, A. D. (1991). Persistent neurotoxicity of systemically administered interferon-alpha. Neurology, 41, 672–676.PubMedGoogle Scholar
  16. Pavol, M. A., Meyers, C. A., Rexer, J. L., Valentine, A. D., Mattis, P. J., & Talpaz, M. (1995). Pattern of neurobehavioral deficits associated with interferon-alfa therapy for leukemia. Neurology, 45, 947–950.PubMedGoogle Scholar
  17. Plata-Salaman, C. R. (1998). Cytokines and anorexia: a brief overview. Seminars in Oncology, 25Supplement 1, 64–72.PubMedGoogle Scholar
  18. Smith, A., Tyrrell, D., Coyle, K., & Higgins, P. (1988). Effects of interferon alpha on performance in man: a preliminary study. Psychopharmacology, 96, 414–416PubMedCrossRefGoogle Scholar
  19. Strite, D., Valentine, A. D., & Meyers, C. A. (1997). Manic episodes in two patients treated with interferon alpha. Journal of Neuropsychiatry and Clinical Neurosciences, 9, 273–276.PubMedGoogle Scholar
  20. Taylor, J. L. & Grossberg, S. E. (1998). The effects of interferon-α on the production and action of other cytokines. Seminars in Oncology, 25Supplement 1, 23–29.PubMedGoogle Scholar
  21. Valentine, A. D., Meyers, C. A., & Talpaz, M. (1995). Treatment of neurotoxic side effects of interferon-α with naltrexone. Cancer Investigation, 13, 561–566.PubMedCrossRefGoogle Scholar
  22. Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E., & Hauser, P. (1998). Mood and cognitive side effects of interferon-α therapy. Seminars in Oncology, 25Supplement 1, 39–47.PubMedGoogle Scholar

Copyright information

© Kluwer Academic/Plenum Publishers 1999

Authors and Affiliations

  • Christina A. Meyers
    • 1
  1. 1.Department of Neuro-OncologyThe University of Texas M. D. Anderson Cancer CenterHouston

Personalised recommendations